HOME >> BIOLOGY >> NEWS
Centocor & Schering-Plough next generation biologic promising in Phase 2 rheumatoid arthritis trial

SAN DIEGO, Calif., November 16, 2005 -- Results from a Phase 2 rheumatoid arthritis (RA) study assessing the safety and efficacy of golimumab (CNTO 148), a fully-human anti-TNF-alpha therapy, showed that it achieved the primary endpoint of the study. In this dose-ranging trial, more than 60 percent of patients with moderately to severely active RA treated with golimumab and methotrexate (MTX) experienced at least 20 percent improvement in arthritis symptoms at week 16. Additionally, one-quarter of patients receiving golimumab and MTX achieved remission as evaluated by Disease Activity Score 28 (DAS28). These findings will be presented this week at the American College of Rheumatology 2005 Annual Scientific Meeting.

"When treating a debilitating disease like RA, it is important to have several treatment options, and we are encouraged by the safety and efficacy data we have seen thus far for golimumab," said Jonathan Kay, MD, Director, Clinical Trials, Rheumatology Unit, Massachusetts General Hospital, Associate Clinical Professor of Medicine, Harvard University School of Medicine and lead study investigator.

Golimumab, developed by Centocor, Inc. and Schering-Plough, is a fully-human anti-TNF-alpha IgG1 monoclonal antibody that targets and neutralizes both the soluble and the membrane-bound form of TNF-alpha. Golimumab is currently being investigated for administration by either subcutaneous (SC) injection or intravenous (IV) infusion.

Data from the study showed that significantly more patients in all groups receiving SC injections of golimumab plus MTX achieved ACR 50 response (marked improvement in arthritis symptoms according to the American College of Rheumatology scoring criteria) versus patients receiving placebo plus MTX. Adults with active RA for at least three months' duration despite MTX therapy were randomized to one of five treatment groups: placebo every two weeks or golimumab 50 or 100 mg every two weeks or every four wee
'"/>

Contact: Michael Parks
215-325-4010
Centocor, Inc.
16-Nov-2005


Page: 1 2 3 4

Related biology news :

1. ASBMB Schering-Plough Award lecture to focus on histone modifications in transcription
2. Cardiac patches stimulate regeneration, improve function after heart attack
3. Serica scientists win AOSSM Award for ACL (knee) tissue regeneration in preclinical study
4. Critical protein prevents DNA damage from persisting through generations
5. Early environmental exposure may accelerate age-related neurodegeneration
6. First demonstration of new hair follicle generation in an animal model
7. Enhanced environment restores memory in mice with neurodegeneration
8. Liver regeneration may be simpler than previously thought
9. Invasive grass may impede forest regeneration
10. Research project tackles regeneration gap
11. Whole body regeneration from a blood vessel

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/5/2020)... ... 2020 , ... In September 2016, stem cell biotechnology company ... the first, and still only, available technology that provides the cell-specific count or ... about the number and quality of therapeutic tissue stem cells are unable to ...
(Date:3/3/2020)... ... March 03, 2020 , ... Amplify Surgical, Inc., today announces that the company ... System. , The landmark case was performed by Dr. Ali Najafi at ... noted, “dualX has completely changed the game for expandable interbodies. The ability to ...
(Date:3/2/2020)... CHICAGO (PRWEB) , ... March 02, 2020 , ... ... attendance at the 71st annual Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy ... in Chicago, Illinois. Pittcon is the world’s leading annual conference and exposition on ...
Breaking Biology News(10 mins):
(Date:2/21/2020)... Ontario (PRWEB) , ... February 20, 2020 , ... In ... GMT/UK) join guest speakers from Synteract including Lisa Dilworth, BS, MS, Vice ... discussion about these challenges, with feasible strategies and solutions to support patients, sites and ...
(Date:2/19/2020)... ... 2020 , ... Shoreline Biome, a microbiome research ... recently unveiled a novel DNA isolation product. , Shoreline Rapid Prep is a ... weight (HMW) single-stranded DNA (ssDNA) in excess of 40 kB from Gram-negative bacteria, ...
(Date:2/11/2020)... ... February 11, 2020 , ... Synagro ... North America, today announced that the City of Fort Worth has partnered with ... needs. Commencing in April of 2020, Synagro will assume operation of the city’s ...
(Date:2/3/2020)... (PRWEB) , ... February 03, 2020 , ... ... offices in Cambridge, MA, announce that OmniType, the 11-locus, single tube multiplex successor ... OmniType is a best-in-class product featuring locus-multiplexing and short library preparation, for HLA ...
Breaking Biology Technology:
Cached News: